CD25-based graft-versus-host disease prophylaxis after haploidentical hematopoietic stem cell transplantation: comparison of two prophylactic strategies.
It is suggested that a higher-dose anti-CD25, methotrexate-free prophylactic approach may reduce acute GVHD and improve GRFS after haplo-HSCT, while its effects on long-term disease control and survival require confirmation in multicenter randomized trials.
Abstract
Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is widely used for hematologic malignancies, yet balancing graft-versus-host disease (GVHD) prophylaxis and immune reconstitution remains challenging. In this prospective, nonrandomized study, we compared a higher-dose anti-CD25 strategy that omitted methotrexate with a conventional lower-dose anti-CD25 regimen that included methotrexate. Lower cumulative anti-thymocyte globulin exposure was observed in the higher-dose group. From May 2022 to January 2025, 276 patients were enrolled (lower-dose group, n=149; higher-dose group, n=127). After a median follow-up of 28.4 months, the higher-dose strategy was associated with a lower 100-day cumulative incidence of grade III-IV acute GVHD (7.9% vs. 17.5%; adjusted subdistribution hazard ratio, 0.39; 95% confidence interval, 0.18-0.88; p=0.022) and improved graft-versus-host diseasefree, relapse-free survival (GRFS) (adjusted hazard ratio, 0.59; 95% confidence interval, 0.43-0.83; p=0.002). Chronic GVHD, overall survival, disease-free survival, relapse, and non-relapse mortality did not differ significantly between groups. Exploratory immune monitoring showed transiently lower CD4+ T-cell counts at day +30 in the higherdose group, whereas longitudinal immune reconstitution trajectories and infectious complications were broadly comparable. These findings suggest that a higher-dose anti-CD25, methotrexate-free prophylactic approach may reduce acute GVHD and improve GRFS after haplo-HSCT, while its effects on long-term disease control and survival require confirmation in multicenter randomized trials. Trial registration: Chinese Clinical Trial Registry, ChiCTR2200060184.
BACKGROUND
Graft-versus-host disease (GvHD) remains one of the most significant complications of hematopoietic stem cell transplantation (HSCT). Abatacept, a selective T-cell costimulation modulator, is a relatively novel prophylactic agent, though pediatric data remain limited.
PROCEDURE
A systematic review and meta...
M. Kruizinga, Anne B. Verbeek, C. Lindemans et al.· Pediatric Blood & Cancer· 0 citations
Relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem-cell transplantation (allo-HSCT), particularly with extramedullary disease (EMD), has a dismal prognosis. The efficacy and durability of allogeneic chimeric antigen receptor T cell (allo-CAR-T) therapy in this setting remain...
Rui Liu, Jian Zhang, Ying Li et al.· Cancer Immunology and Immuno...· 0 citations
Background Post-cyclophosphamide (PTCy)-based GVHD prophylaxis has shown significant success in haploidentical transplants. The potential of PTCy in adult umbilical blood transplantation (UCBT) remains unclear due to concerns about engraftment, given the limited number of CD34+ cells. This study aimed to explore the pr...
Yun-Tian Ding, Wei Xiao, Ya-Qun Wang et al.· Frontiers in Immunology· 0 citations
Graft-versus-host disease (GVHD) remains a major limitation of allogeneic hematopoietic stem cell transplantation (alloHSCT) outcomes. The increasing use of post-transplant cyclophosphamide (PTCy) and antithymocyte globulin (ATG) has expanded beyond haploidentical transplantation to matched related (MRD) and unrelated...
C. Martínez, L. Bento, M. Salas et al.· Bone Marrow Transplantation· 0 citations